Stockhub

Oryzon Genomics S.A.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

3 September 2022

  • curprev 06:3406:34, 3 September 2022 95.149.241.133 talk 785 bytes +785 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Oryzon Genomics S.A., a clinical phase biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS..."
Retrieved from "https://stockhub.co/research/Oryzon_Genomics_S.A."